Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing

PURPOSE Screening and prevention decisions for women at increased risk of developing breast cancer depend on genetic and clinical factors to estimate risk and select appropriate interventions. Integration of polygenic risk into clinical breast cancer risk estimators can improve discrimination. However, correlated genetic effects must be incorporated carefully to avoid overestimation of risk. MATERIALS AND METHODS A novel Fixed-Stratified method was developed that accounts for confounding when adding a new factor to an established risk model. A combined risk score (CRS) of an 86–single-nucleotide polymorphism polygenic risk score and the Tyrer-Cuzick v7.02 clinical risk estimator was generated with attenuation for confounding by family history. Calibration and discriminatory accuracy of the CRS were evaluated in two independent validation cohorts of women of European ancestry (N = 1,615 and N = 518). Discrimination for remaining lifetime risk was examined by age-adjusted logistic regression. Risk stratification with a 20% risk threshold was compared between CRS and Tyrer-Cuzick in an independent clinical cohort (N = 32,576). RESULTS Simulation studies confirmed that the Fixed-Stratified method produced accurate risk estimation across patients with different family history. In both validation studies, CRS and Tyrer-Cuzick were significantly associated with breast cancer. In an analysis with both CRS and Tyrer-Cuzick as predictors of breast cancer, CRS added significant discrimination independent of that captured by Tyrer-Cuzick (P < 10−11 in validation 1; P < 10−7 in validation 2). In an independent cohort, 18% of women shifted breast cancer risk categories from their Tyrer-Cuzick–based risk compared with risk estimates by CRS. CONCLUSION Integrating clinical and polygenic factors into a risk model offers more effective risk stratification and supports a personalized genomic approach to breast cancer screening and prevention.

[1]  James Y. Dai,et al.  Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk , 2020, Journal of the National Cancer Institute.

[2]  Jennifer L. Caswell-Jin,et al.  Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer. , 2020, JAMA.

[3]  H. Brenner,et al.  Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer. , 2019, JAMA oncology.

[4]  Gretchen L. Gierach,et al.  Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines. , 2019, JAMA oncology.

[5]  S. Astley,et al.  A case–control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density , 2019, International journal of cancer.

[6]  A. Hollestelle,et al.  Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families , 2019, Journal of Medical Genetics.

[7]  X. Castells,et al.  A systematic review and quality assessment of individualised breast cancer risk prediction models , 2019, British Journal of Cancer.

[8]  Gord Glendon,et al.  10-year performance of four models of breast cancer risk: a validation study. , 2019, The Lancet. Oncology.

[9]  M. García-Closas,et al.  BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors , 2019, Genetics in Medicine.

[10]  Kristen S Purrington,et al.  Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes , 2018, American Journal of Human Genetics.

[11]  W. Willett,et al.  Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case–control study , 2018, PLoS medicine.

[12]  C. Turnbull,et al.  Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group , 2018, Journal of Medical Genetics.

[13]  S. Astley,et al.  Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction , 2018, JAMA oncology.

[14]  Alexander Gutin,et al.  Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. , 2017, JCO precision oncology.

[15]  Jack Cuzick,et al.  Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Cuzick,et al.  The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case–control study , 2016, Journal of Medical Genetics.

[17]  Nilanjan Chatterjee,et al.  iCARE: R package to build, validate and apply absolute risk models , 2016, bioRxiv.

[18]  A. Whittemore,et al.  Genetic modifiers of CHEK2*1100delC associated breast cancer risk , 2016, Genetics in Medicine.

[19]  Mark E. Robson,et al.  Counselling framework for moderate-penetrance cancer-susceptibility mutations , 2016, Nature Reviews Clinical Oncology.

[20]  S. Cummings,et al.  Breast cancer risk prediction using a clinical risk model and polygenic risk score , 2016, Breast Cancer Research and Treatment.

[21]  Sofia Khan,et al.  Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families , 2016, Breast Cancer Research and Treatment.

[22]  Rochelle Fu,et al.  Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation , 2016, Annals of Internal Medicine.

[23]  G. Giles,et al.  Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[24]  Jane E. Carpenter,et al.  Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants , 2015, JNCI Journal of the National Cancer Institute.

[25]  Satish Bhatnagar,et al.  T E C H N I C a L a D V a N C E Open Access , 2022 .

[26]  J. Murabito,et al.  Genome-wide association studies of age at menarche and age at natural menopause , 2014, Molecular and Cellular Endocrinology.

[27]  Erik Ingelsson,et al.  Genome-wide association studies of obesity and metabolic syndrome , 2014, Molecular and Cellular Endocrinology.

[28]  Anne Marie McCarthy,et al.  Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women , 2013, Breast Cancer Research and Treatment.

[29]  David A. Hinds,et al.  Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information , 2010, Journal of the National Cancer Institute.

[30]  M. Thun,et al.  Performance of Common Genetic Variants in Breast-cancer Risk Models , 2022 .

[31]  M. Gail Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. , 2009, Journal of the National Cancer Institute.

[32]  J. Hopper,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.

[33]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[34]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[35]  A Howell,et al.  Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme , 2003, Journal of medical genetics.

[36]  J Benichou,et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.

[37]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[38]  Peter Dalgaard,et al.  R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .